-
Clinical evidence shows that ProFound Detection's AI can help reduce breast cancer interval cancer (IC) rates and reduce recall rates without adding false negatives.
-
Findings reveal a significant reduction in radiology interpretation workload
-
Detection of breast artery calcification (BAC) by ProFound Heart Health may serve as a biomarker to assess broader cardiovascular disease in women
NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) helps healthcare providers accurately and reliably detect cancer early and improve patient outcomes. We are a global leader in clinically proven AI-powered solutions to help you. will focus on scientific presentations, including award-winning posters, at the European Congress of Radiology (ECR) Annual Congress, to be held from February 28 to March 3, 2024 in Vienna, Austria. The company also announced that it will focus on its new releases that leverage AI. ProFound Detection Solutions is showcasing its complete Breast Health Suite at booth X1 AI-35.
“The data presented at ECR shows that the efficiency of mammography breast screening, from reducing workload without compromising accuracy, to potentially lowering interval cancer rates and speeding diagnosis of true-positive cases, will increase the efficiency of mammography breast screening. “These findings highlight the transformative power of ProFound AI to improve breast health care,” said Dana Brown, President and CEO of iCAD. I am.
“Additionally, we are excited to introduce new workstation features that improve the readability of iCAD's flagship solution, ProFound Detection,” continued Brown. “This includes limiting lesion marking to the three highest-scoring lesions, which can be color-coded based on lesion score. Additionally, the ProFound Scorecard is based on a facility's actual data. For radiologists, these latest enhancements make mammogram interpretation even better and easier. .”
new research
The following three oral presentations and award-winning poster presentations highlight clinical research to be presented at ECR 2024. Click here for detailed information. here.
-
Friday, March 1st, 8 a.m. to 9 a.m. RPS1202 – Adding artificial intelligence (AI) case grade scores to breast screening programs to reduce screen reading workload: A retrospective study. A study conducted by A. Nitrosi et al. Italy's Reggio Emilia breast cancer screening program evaluates integrating iCAD's Artificial Intelligence Mammography Case Scoring (AI-CMS) into its breast cancer screening program to reduce screen reading workload without compromising accuracy. It was intended to. The study analyzed data from 31,747 screening tests involving 92 proven tumors and simulated two integrated AI and human reading protocols (ProFound AI 2D System). As a result, deploying ProFound AI-CMS significantly reduces the number of human reads and workload by 24.8% to 30.6%, slightly improves recall, and reduces false readings at 10% and 15% case score thresholds. We found that no increase in negativity was observed.
-
Sunday, March 3rd, 9:30am-11am RPS2305 – Retrospective evaluation of interval breast cancer: Can AI diagnostic software be used to reduce the number of interval breast cancers? In the study, conducted by Jonas Subelack and colleagues, researchers from the Universities of St. Gallen and Krebsliga Ostschweiz in Switzerland and the Radiology am Theater in Germany found that iCAD's ProFound AI ). The study analyzed data from 151,245 screening mammograms from 2010 to 2019 and identified 264 ICs in which considered-normal cancer was detected within 24 months of screening. The expected results are that the software will improve the IC detection rate compared to the initial screening, and the detection accuracy will be influenced by the set threshold. The study shows that the software is expected to outperform radiologists in detecting IC, suggesting it could be integrated into mammography screening to reduce IC.
-
March 3rd (Sunday) 11:30 a.m. – 12:30 p.m. RPS 2405 – Adding artificial intelligence (AI) case grade scores to breast cancer screening programs to potentially overcome delays in true-positive cases: A retrospective study. Retrospective study in the Italian Reggio Emilia Breast Screening Program led by A. Nitrosi et al. Evaluate the effectiveness of implementing iCAD's ProFound AI case scoring strategy into breast cancer screening programs to speed up the reading process for potentially true-positive cases, requiring readings within two weeks The purpose is to ensure compliance with regulations. The study, which analyzed data from 32,012 2D mammography screening exams, utilized the ProFound AI 2D system. The AI-generated case score represents the algorithm's confidence in malignancy and was used to prioritize readings. As a result, screening test readings above a certain case score threshold identify 61% to 89% of screening test-detected cancers, while screening test readings are required for 5.4% to 20% of cancers detected by screening tests. % only. In particular, by prioritizing test readings with case scores greater than 40%, we were able to recall a large proportion (85%) of true-positive cases in a short period of time.
-
ECR 2024 Award – certificate
Electronic poster presentation – Breast artery calcification (BAC): a substitute for atherosclerotic calcium in medium and large vessels. In this retrospective study by C. Parghi et al., researchers investigated breast artery calcification (BAC) detected by ProFound AI Heart Health on Solis mammography screening mammograms and observed on CT images within 12 months of acquisition. We investigated its correlation with the degree of atherosclerosis. Mammogram. Analysis of data from 1,449 women showed that a BAC score of 3 or higher was associated with the development of clinically significant atherosclerosis in large and medium-sized vessels compared with a BAC score of <3. The rate was found to be significantly higher. Specifically, this percentage increased from 11.0. % to 31.0% (p < 0.001). For BAC scores ≥3, the sensitivity, specificity, and accuracy for detecting clinically significant atherosclerosis were 21.8%, 92.9%, and 83.8%, respectively. These findings suggest that quantitative assessment of BAC may provide insight and identify patients who require further cardiovascular screening.
Chirag PargiM.D., chief medical officer of Solis Mammography and a pioneer in the use of mammography to assess BAC, received this award. certificate This poster presentation was awarded. “We are encouraged by our findings that highlight the potential of thoracic artery calcification (BAC) assessment to revolutionize access to cardiovascular risk assessment. demonstrate the importance of quantitative BAC scores in indicating a high likelihood of significant atherosclerosis and identify individuals who may benefit from further cardiovascular screening. We continue to advocate for screening mammography as a portal for screening for both breast cancer and cardiovascular risk, the top two causes of death for women worldwide.”
ProFound Detection enhancements for 2D and 3D mammography
New workstation features included in ProFound Detection's 3rd generation solution update are designed to improve the readability of iCAD results through a configuration option that limits the number of lesion marks displayed in the 3D view to three . This improvement allows radiologists to interpret the most important information without multiple markings, streamlining the diagnostic process and enabling more efficient decision-making.
In addition, ProFound Scorecard introduces color-coded lesion markings and case scores, providing an intuitive visual aid that allows radiologists to quickly identify the level of suspicion for detected abnormalities. This color-coded system provides a concise and comprehensive display of the severity of detected lesions and overall cases based on the number of cancers per screening population, further facilitating accurate diagnosis and case prioritization. facilitate.
Additionally, support for the ability to fine-tune score ranges based on real-world data allows users to customize the detection system according to specific clinical needs, supporting performance and adaptability to different patient populations.
Finally, iCAD emphasizes an expanded cloud platform and subscription licensing plans, which greatly increase deployment flexibility. iCAD's new Success Program provides a full range of continuous software updates to ensure customers have the latest versions of iCAD's AI products, system maintenance and customer support.
To learn more about iCAD's presence at the ECR 2024 Annual Meeting, or to schedule time with the iCAD team virtually or in-person, please visit: www.icadmed.com/ecr-2024
About iCAD Co., Ltd.
iCAD, Inc. (NASDAQ: ICAD) delivers clinically proven, AI-powered solutions that enable healthcare providers to accurately and reliably detect cancer early and improve patient outcomes. We are a global leader on a mission to create a world where cancer is no longer hidden. Headquartered in Nashua, New Hampshire, iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment, and risk assessment. ProFound is used by thousands of providers serving millions of patients and is available in more than 50 countries. iCAD estimates that in the past five years alone he has read more than 40 million mammograms worldwide, of which nearly 30% were tomosynthesis. For more information, including the latest regulatory approvals, please visit: www.icadmed.com.
Forward-looking statements
Certain statements contained in this news release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. This includes statements regarding expanded access to our products, improved performance, accelerated adoption and expected benefits. Profound AI®, the benefits of our products, and future prospects for our technology platform and products. Such forward-looking statements involve a number of known and unknown risks that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by us. , uncertainties, and other factors. Such a positive statement. These factors include our ability to achieve our business and strategic goals, patient willingness to undergo mammography screening given the risk of potential exposure to COVID-19, and whether mammography screening is considered an essential procedure. This includes, but is not limited to, whether the , whether ProFound AI proves to improve read efficiency, improve specificity and sensitivity, reduce false positives, or otherwise be more beneficial to patients and clinicians, supply and manufacturing constraints; the impact of risks and difficulties on our ability to fulfill orders, the level of uncertainty regarding future sales, our defense in litigation matters, the protection of our patents and other proprietary rights, the market acceptance of our products, the potential technical obsolescence of our products; the effects of increased competition, changes in government regulations, Medicare or other reimbursement policies, risks associated with our existing and future obligations, competitive factors and declines in the economies or markets we serve; and other risks detailed in the Company's filings with the Securities and Exchange Commission. “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “plan”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. . Readers are cautioned not to place undue reliance on these forward-looking statements. These statements speak only as of the date on which they are made. We undertake no obligation to provide updates to the information contained in this release. For additional disclosures regarding these and other risks faced by iCAD, please see the disclosures contained in our public filings with the Securities and Exchange Commission. This disclosure is available in the “Investors'' section of the following website: http://www.icadmed.com On the SEC website: http://www.sec.gov.
contact address
Media inquiries: pr@icadmed.com
Investor inquiries: ir@icadmed.com